DB-959Na
DB-959Na is in phase II clinical trials for the treatment of Alzheimer's disease.
The compound was co-developed by Bayer and T3D Therapeutics, then licensed to DARA BioSciences for the worldwide rights.
General Information
Update Date：2015-11-30
- Drug Name：
- DB-959Na
- Research Code：
- DB-959Na; T3D-959
- Trade Name：
- MOA：
- PPAR agonist
- Indication：
- Alzheimer's disease (AD)
- Status：
- Phase II (Active)
- Company：
- DARA BioSciences (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-30
|
Molecular Weight | 443.47 | ||||||||||||
| Formula | C25H26NO5 • Na | |||||||||||||
| CAS No. |
1257641-15-8 (DB-959); 1258076-66-2 (DB-959Na); |
|||||||||||||
| Chemical Name | 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-methoxyphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro-, sodium salt (1:1), (1S)- | |||||||||||||
| DB-959 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||